Literature DB >> 20423715

Disruption of Smad-dependent signaling for growth of GST-P-positive lesions from the early stage in a rat two-stage hepatocarcinogenesis model.

Ryohei Ichimura1, Sayaka Mizukami1, Miwa Takahashi2, Eriko Taniai1, Sayaka Kemmochi3, Kunitoshi Mitsumori1, Makoto Shibutani1.   

Abstract

To clarify the involvement of signaling of transforming growth factor (TGF)-β during the hepatocarcinogenesis, the immunohistochemical distribution of related molecules was analyzed in relation with liver cell lesions expressing glutathione S-transferase placental form (GST-P) during liver tumor promotion by fenbendazole, phenobarbital, piperonyl butoxide, or thioacetamide, using rats. Our study focused on early-stage promotion (6weeks after starting promotion) and late-stage promotion (57weeks after starting promotion). With regard to Smad-dependent signaling, cytoplasmic accumulation of phosphorylated Smad (phospho-Smad)-2/3 - identified as Smad3 by later immunoblot analysis - increased in the subpopulation of GST-P(+) foci, while Smad4, a nuclear transporter of Smad2/3, decreased during early-stage promotion. By late-stage promotion, GST-P(+) lesions lacking phospho-Smad2/3 had increased in accordance with lesion development from foci to carcinomas, while Smad4 largely disappeared in most proliferative lesions. With regard to Smad-independent mitogen-activated protein kinases, GST-P(+) foci that co-expressed phospho-p38 mitogen-activated protein kinase increased during early-stage promotion; however, p38-downstream phospho-activating transcriptional factor (ATF)-2, ATF3, and phospho-c-Myc, were inversely downregulated without relation to promotion. By late-stage promotion, proliferative lesions downregulated phospho-ATF2 and phospho-c-Myc along with lesion development, as with downregulation of phospho-p38 in all lesions. These results suggest that from the early stages, carcinogenic processes were facilitated by disruption of tumor suppressor functions of Smad-dependent signaling, while Smad-independent activation of p38 was an early-stage phenomenon. GST-P(-) foci induced by promotion with agonists of peroxisome proliferator-activated receptor-α did not change Smad expression, suggesting an aberration in the Smad-dependent signaling prerequisites for induction of GST-P(+) proliferative lesions.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20423715     DOI: 10.1016/j.taap.2010.04.016

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Role of Vitamin D as Protective Agent against Induced Liver Damage in Male Rats.

Authors:  M K Hassani
Journal:  Arch Razi Inst       Date:  2021-12-30

2.  Toxic effects of thioacetamide-induced femoral damage in New Zealand white rabbits by activating the p38/ERK signaling pathway.

Authors:  L Cheng; Y Li; Y Yao; X Jin; H Ying; B Xu; J Xu
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

3.  Amelioration of thioacetamide-induced liver toxicity in Wistar rats by rutin.

Authors:  Seema Zargar; Tanveer A Wani; Abir Abdullah Alamro; Majid Ahmad Ganaie
Journal:  Int J Immunopathol Pharmacol       Date:  2017-06-07       Impact factor: 3.219

4.  Expression Characteristics of Genes Hypermethylated and Downregulated in Rat Liver Specific to Nongenotoxic Hepatocarcinogens.

Authors:  Yuko Ito; Kota Nakajima; Yasunori Masubuchi; Satomi Kikuchi; Fumiyo Saito; Yumi Akahori; Meilan Jin; Toshinori Yoshida; Makoto Shibutani
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

5.  Chemical Profile of Cyperus laevigatus and Its Protective Effects against Thioacetamide-Induced Hepatorenal Toxicity in Rats.

Authors:  Iriny M Ayoub; Marawan A El-Baset; Mai M Elghonemy; Samir A E Bashandy; Fatma A A Ibrahim; Omar A H Ahmed-Farid; Abd El-Nasser G El Gendy; Sherif M Afifi; Tuba Esatbeyoglu; Abdel Razik H Farrag; Mohamed A Farag; Abdelsamed I Elshamy
Journal:  Molecules       Date:  2022-10-01       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.